Lung Cancer Surgery Market - Global Forecast 2026-2032

The Lung Cancer Surgery Market size was estimated at USD 6.94 billion in 2025 and expected to reach USD 7.60 billion in 2026, at a CAGR of 10.82% to reach USD 14.25 billion by 2032.

Lung cancer surgery is evolving alongside improvements in screening, imaging, anesthetic management, perioperative care, and systemic therapy. Surgical decision-making increasingly depends on tumor stage, histology, molecular findings, cardiopulmonary fitness, comorbidities, and the availability of multidisciplinary expertise. The field spans diagnostic resections, curative-intent procedures, parenchyma-sparing techniques, and complex operations for locally advanced disease. Care pathways are also being shaped by enhanced recovery protocols, minimally invasive approaches, and closer integration between surgery, radiation oncology, medical oncology, pathology, and respiratory medicine.

The landscape is shifting from surgery considered in isolation toward coordinated, stage-specific treatment planning. Earlier detection can increase the proportion of patients evaluated for resection, while high-resolution imaging, bronchoscopy, image-guided biopsy, and functional testing support more precise selection. Video-assisted and robotic-assisted techniques are expanding where expertise and infrastructure permit, with potential benefits such as smaller incisions and shorter recovery, although outcomes remain dependent on patient selection, surgeon experience, conversion management, and institutional protocols. Neoadjuvant and adjuvant therapies are also changing timing, eligibility, and perioperative coordination. Persistent barriers include late diagnosis, unequal access to specialized centers, postoperative complications, workforce constraints, and variations in reimbursement and referral systems.

Artificial intelligence is being applied across the lung cancer surgical pathway, including nodule detection, image interpretation, radiomic assessment, operative planning, risk stratification, and postoperative monitoring. These tools may help prioritize suspicious findings, support three-dimensional visualization, identify anatomical variation, and flag patients at elevated risk of complications or prolonged recovery. Their practical value depends on representative training data, prospective validation, interoperability with clinical systems, explainability, cybersecurity, and clinician oversight. AI should complement rather than replace multidisciplinary judgment, particularly when imaging findings, functional status, pathology, and patient preferences point in different directions.

North America benefits from advanced thoracic oncology infrastructure, broad availability of minimally invasive surgery, and established multidisciplinary programs, but access and affordability vary across populations. Europe combines strong clinical research networks with differing national pathways, workforce capacity, and reimbursement policies. Asia-Pacific contains leading high-volume surgical centers alongside substantial rural and urban disparities, with Japan, South Korea, China, Australia, and India reflecting distinct care models. Latin America continues to face challenges involving delayed diagnosis, uneven specialist distribution, and access to complex surgery, while selected urban centers are expanding advanced capabilities. The Middle East is developing tertiary oncology capacity, yet referral concentration and cross-border care remain important considerations. Africa faces pronounced shortages in screening, diagnostic infrastructure, thoracic specialists, and postoperative support, making basic access and referral strengthening central priorities.

ASEAN countries show varied diagnostic access, surgical capacity, and public-private care structures, creating opportunities for regional training and referral collaboration. BRICS members combine large patient populations with significant differences in infrastructure, affordability, and specialist distribution, making scalable diagnostics and workforce development especially relevant. The European Union benefits from cross-border research and regulatory cooperation, while national implementation remains uneven. G7 health systems generally have strong specialist capacity and data resources but continue to address aging populations, service pressure, and cost-effectiveness. GCC countries are strengthening tertiary oncology services and may use centralized expertise and digital coordination to improve complex-case management. NATO members encompass diverse health systems, but preparedness, trauma-informed surgical capability, and interoperable clinical standards can support resilience and collaboration.

Australia combines sophisticated thoracic services with geographic access challenges, particularly for remote communities. Brazil and Mexico must address regional disparities, delayed presentation, and uneven access to specialized surgery. Canada and the United States have advanced centers and minimally invasive expertise, alongside concerns about affordability, geographic inequity, and continuity of care. China is expanding thoracic oncology capacity and technological adoption while managing substantial variation between metropolitan and less-served areas. India faces a large burden of late presentation and limited specialist access outside major centers. Japan and South Korea have mature surgical ecosystems, strong imaging capabilities, and established high-volume institutions. France, Germany, Italy, Spain, and the United Kingdom possess substantial specialist capacity, with ongoing attention to waiting times, workforce sustainability, pathway integration, and equitable regional access. Russia’s care environment reflects geographic scale, uneven infrastructure, and the need for consistent referral and perioperative support.

Industry leaders should prioritize multidisciplinary pathways that connect screening, diagnosis, staging, surgery, systemic therapy, rehabilitation, and survivorship. Investments should focus on surgeon and operating-room training, minimally invasive capability where clinically appropriate, standardized enhanced recovery protocols, and reliable postoperative monitoring. Organizations should validate AI tools prospectively, establish governance for bias and accountability, and integrate decision support into existing workflows rather than creating parallel systems. Partnerships with regional hospitals can improve referral speed and enable shared expertise, while patient navigation can reduce diagnostic and treatment delays. Performance management should track clinically meaningful outcomes such as complications, readmissions, time to treatment, functional recovery, quality of life, and equity by geography and socioeconomic group.

This executive summary uses the defined market scope of lung cancer surgery and organizes findings across clinical practice, technology, health-system capacity, geography, and stakeholder groups. The analysis emphasizes verifiable patterns documented through established clinical guidance, peer-reviewed research, health-system evidence, regulatory materials, and publicly available institutional or governmental sources. It distinguishes broadly observed developments from context-dependent implementation considerations and avoids unsupported numerical claims. Regional, group, and country perspectives are integrated qualitatively, with attention to diagnostic pathways, surgical capability, multidisciplinary coordination, access, workforce, and technology governance. Clinical decisions should be based on current local guidelines, patient-specific assessment, and consultation with qualified specialists.

Lung cancer surgery is becoming more precise, less invasive, and more closely integrated with the wider oncology pathway. The greatest benefits will come not from technology alone, but from combining earlier detection, accurate staging, expert multidisciplinary selection, safe surgical execution, effective recovery support, and equitable referral. Regional and national differences mean that priorities must be adapted to local infrastructure and patient needs. Leaders who pair validated innovation with workforce development, outcome measurement, responsible AI governance, and stronger care coordination will be better positioned to improve the consistency and quality of surgical care.